Transverse myelitis secondary prevention
Jump to navigation
Jump to search
|
Transverse myelitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Transverse myelitis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Transverse myelitis secondary prevention |
|
Risk calculators and risk factors for Transverse myelitis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- Secondary prevention after transverse myelitis (TM) means preventing another inflammatory spinal-cord attack after the initial event. There is no single relapse-prevention regimen for every patient because transverse myelitis is a clinical syndrome with several possible causes; preventive treatment must follow the final disease-specific diagnosis.[1]
- Routine long-term immunotherapy is not established after a single, comprehensively evaluated, apparently idiopathic monophasic episode. In contrast, long-term relapse-prevention therapy is generally required when the episode establishes a relapsing neuroinflammatory disease, particularly aquaporin-4 immunoglobulin G (AQP4-IgG)-positive neuromyelitis optica spectrum disorder (NMOSD).[2]
| Clinical principle: Do not prescribe lifelong immune therapy merely because the first event was labelled “transverse myelitis.” First determine whether the attack was monophasic and idiopathic or was a manifestation of AQP4-IgG-positive NMOSD, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), multiple sclerosis, another systemic inflammatory disease, or an infection. The cause determines whether preventive therapy is indicated and which treatment is appropriate.[1] |
Secondary Prevention
Etiology-directed prevention
| Clinical category | Recommended relapse-prevention approach | Evidence and consensus position |
|---|---|---|
| Apparently idiopathic, monophasic transverse myelitis | Do not routinely begin indefinite maintenance immunotherapy after one thoroughly investigated monophasic event. Arrange individualized neurological follow-up. A new objective attack should trigger renewed diagnostic evaluation rather than automatic continuation of the “idiopathic” label. | No disease-specific maintenance regimen has been established. Contemporary expert review emphasizes that preventive treatment is appropriate for selected etiologies rather than for the transverse-myelitis syndrome as a whole.[1] |
| AQP4-IgG-positive NMOSD presenting with myelitis | Start long-term attack-prevention immunotherapy promptly once the NMOSD diagnosis is established. Guideline-supported monoclonal-antibody options include eculizumab, ravulizumab, inebilizumab, rituximab, or satralizumab, selected according to efficacy, onset of action, comorbidities, safety, age, pregnancy plans, patient preference, adherence, access, and cost.[2][3] | The Neuromyelitis Optica Study Group (NEMOS) recommends initiating long-term immunotherapy with one of these monoclonal antibodies when available and accessible. The international Delphi consensus supports individualized selection and switching among approved preventive therapies.[2][3] |
| Double-negative NMOSD | Confirm that both AQP4-IgG and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) are negative using appropriate assays, reconsider alternative diagnoses, and obtain specialist review. Long-term immunotherapy is generally considered after a second attack or after a severe first attack. | NEMOS recommendation B10 supports initiation after a second attack or a severe first attack; no preventive therapy is specifically approved for this heterogeneous group.[2] |
| MOGAD presenting with myelitis | Do not assume that every first MOGAD attack requires indefinite maintenance therapy because a monophasic course is common. Discuss long-term immunotherapy with a neuroimmunology expert when a relapse occurs; the decision after a first attack should be individualized according to attack severity, recovery, age, treatment risk, and expert judgment.[4] | The 2025 French practice guideline states that long-term immune-active therapy may be proposed particularly after relapse and recommends expert-center follow-up. The European Union pediatric myelin oligodendrocyte glycoprotein consortium recommends beginning maintenance treatment after a first relapse in children.[4][5] |
| Transverse myelitis attributed to another defined relapsing inflammatory disease | Use the disease-modifying or immunosuppressive strategy recommended for the confirmed underlying disorder; do not substitute a generic transverse-myelitis regimen. For example, myelitis attributed to multiple sclerosis is managed according to multiple-sclerosis disease-modifying therapy, while systemic inflammatory disease requires its own specialist-directed treatment. | Modern transverse-myelitis management is diagnosis-specific because prognosis, recurrence risk, and preventive treatment differ substantially by etiology.[1] |
Starting, continuing, and stopping preventive immunotherapy
- Start promptly in AQP4-IgG-positive NMOSD: each attack can cause permanent disability, and NEMOS recommends initiating long-term preventive immunotherapy once the diagnosis is established.[2]
- Do not stop stable AQP4-IgG-positive NMOSD therapy routinely: NEMOS recommends continuing immunotherapy in clinically stable patients. If temporary or permanent discontinuation is unavoidable because of adverse effects or patient choice, close specialist monitoring is required because relapse risk may increase after withdrawal.[2]
- Do not use the AQP4-IgG titer alone to predict an attack or stop treatment: antibody titers do not correlate reliably with disease activity, and routine titer monitoring for attack prediction is not generally recommended.[2]
- Individualize MOGAD prevention: long-term treatment is most clearly supported after a confirmed relapse; the benefits of preventing further attacks must be balanced against overtreating a potentially monophasic disease.[4][5]
- Reassess recurrent “idiopathic” disease: before committing a patient to indefinite immunotherapy, re-evaluate the diagnosis and exclude a defined antibody-associated, demyelinating, systemic autoimmune, infectious, neoplastic, vascular, or structural cause.[1]
Follow-up during secondary prevention
- At follow-up, document interval neurological attacks, recovery, adherence, adverse effects, infections, comorbidities, and changes in pregnancy or family-planning goals. Preventive therapy and monitoring should be reviewed by a neurologist experienced in neuroimmunology.[2][4]
- Before and during immune therapy, use the infection screening, immunization, laboratory surveillance, and other safety monitoring required for the selected agent. Vaccination status should be updated according to national recommendations, but treatment of active NMOSD should not be delayed solely because vaccination is incomplete.[2]
- New clinical symptoms compatible with recurrent myelitis should prompt urgent assessment to confirm a true inflammatory attack, with magnetic resonance imaging (MRI) obtained when clinically indicated. A confirmed relapse should prompt assessment of adherence and treatment failure and reconsideration of the underlying diagnosis and preventive regimen. Follow-up imaging should be individualized to the confirmed disease and clinical course.[1]
Interventions outside the scope of secondary prevention
- High-dose glucocorticoids, plasma exchange, and intravenous immunoglobulin used to treat an acute attack are addressed in medical therapy and are not, by themselves, long-term secondary prevention.
- Rehabilitation, mobility care, treatment of pain or spasticity, and management of bladder, bowel, respiratory, skin, bone, and thromboembolic complications remain essential but are supportive or tertiary-prevention measures rather than prevention of another inflammatory myelitis attack.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Tisavipat N, Flanagan EP. Current perspectives on the diagnosis and management of acute transverse myelitis. Expert Review of Neurotherapeutics. 2023;23(4):389-411. Digital object identifier: 10.1080/14737175.2023.2195095.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 Kümpfel T, Giglhuber K, Aktas O, et al.; Neuromyelitis Optica Study Group. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD)—revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. Journal of Neurology. 2024;271(1):141-176. Digital object identifier: 10.1007/s00415-023-11910-z.
- ↑ 3.0 3.1 Paul F, Marignier R, Palace J, et al. International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab. Neurology: Neuroimmunology & Neuroinflammation. 2023;10(4):e200124. Digital object identifier: 10.1212/NXI.0000000000200124.
- ↑ 4.0 4.1 4.2 4.3 Giorgi L, Marignier R, Pique J, et al. French guidelines for the diagnosis and management of MOG antibody-associated disease. Revue Neurologique. 2025;181(7):597-607. Digital object identifier: 10.1016/j.neurol.2025.04.012.
- ↑ 5.0 5.1 Bruijstens AL, Wendel EM, Lechner C, et al. E.U. paediatric MOG consortium consensus: Part 5—Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology. 2020;29:41-53. Digital object identifier: 10.1016/j.ejpn.2020.10.005.